Retinoblastoma

Retinoblastoma is a rare type of eye cancer that usually develops in early childhood, typically before the age of 5. This form of cancer develops in the retina, which is the specialized light-sensitive tissue at the back of the eye that detects light and color.

In children with retinoblastoma, the disease often affects only one eye. However, one out of three children with retinoblastoma develops cancer in both eyes. The most common first sign of retinoblastoma is a visible whiteness in the pupil called "cat's eye reflex" or leukocoria. This unusual whiteness is particularly noticeable in dim light or in photographs taken with a flash. Other signs and symptoms of retinoblastoma include crossed eyes or eyes that do not point in the same direction (strabismus), which can cause squinting; a change in the color of the colored part of the eye (iris); redness, soreness, or swelling of the eyelids; and blindness or poor vision in the affected eye or eyes.

Retinoblastoma is often curable when it is diagnosed early. However, if it is not treated promptly, this cancer can spread beyond the eye to other parts of the body. This advanced form of retinoblastoma can be life-threatening.

When retinoblastoma is associated with a genetic change (mutation) that occurs in all of the body’s cells, it is known as hereditary (or germinal) retinoblastoma. People with this form of retinoblastoma typically develop cancer in both eyes and also have an increased risk of developing several other cancers outside the eye. Specifically, they are more likely to develop a cancer of the pineal gland in the brain (pineoblastoma), a type of bone cancer known as osteosarcoma, cancers of soft tissues (such as muscle) called soft tissue sarcomas, and an aggressive form of skin cancer called melanoma.

Frequency

Retinoblastoma is diagnosed in 250 to 350 children per year in the United States. It accounts for about 4 percent of all cancers in children younger than 15 years.

Causes

Mutations in the RB1 gene are responsible for most cases of retinoblastoma. RB1 is a tumor suppressor gene, which means that it normally regulates cell growth and stops cells from dividing too rapidly or in an uncontrolled way. Most mutations in the RB1 gene prevent it from making any functional protein, so cells are unable to regulate cell division effectively. As a result, certain cells in the retina can divide uncontrollably to form a cancerous tumor. Some studies suggest that additional genetic changes can influence the development of retinoblastoma; these changes may help explain variations in the development and growth of retinoblastoma and other types of tumors in different people.
A small percentage of retinoblastomas are caused by deletions in the region of chromosome 13 that contains the \textit{RB1} gene. Because these chromosomal changes involve several genes in addition to \textit{RB1}, affected children usually also have intellectual disability, slow growth, and distinctive facial features (such as prominent eyebrows, a short nose with a broad nasal bridge, and ear abnormalities).

**Inheritance Pattern**

Researchers estimate that one-third of all retinoblastomas are hereditary, which means that \textit{RB1} gene mutations are present in all of the body’s cells, including reproductive cells (sperm or eggs). People with hereditary retinoblastoma may have a family history of the disease, and they are at risk of passing on the mutated \textit{RB1} gene to the next generation. The other two-thirds of retinoblastomas are non-hereditary, which means that \textit{RB1} gene mutations are present only in cells of the eye and cannot be passed to the next generation.

In hereditary retinoblastoma, mutations in the \textit{RB1} gene appear to be inherited in an autosomal dominant pattern. Autosomal dominant inheritance means that one copy of the altered gene in each cell is sufficient to increase the risk of cancer. A person with hereditary retinoblastoma may inherit an altered copy of the \textit{RB1} gene from one parent, or the altered gene may be the result of a new mutation that occurs in an egg or sperm cell or just after fertilization. For retinoblastoma to develop, a mutation involving the other copy of the \textit{RB1} gene must occur in retinal cells during the person’s lifetime. This second mutation usually occurs in childhood, typically leading to the development of retinoblastoma in both eyes.

In the non-hereditary form of retinoblastoma, typically only one eye is affected and there is no family history of the disease. Affected individuals are born with two normal copies of the \textit{RB1} gene. Then, usually in early childhood, both copies of the \textit{RB1} gene in certain retinal cells acquire mutations. People with non-hereditary retinoblastoma are not at risk of passing these \textit{RB1} gene mutations to their children. However, without genetic testing it can be difficult to tell whether a person with retinoblastoma in one eye has the hereditary or the non-hereditary form of the disease.

**Other Names for This Condition**

- Glioma, retinal
- RB

**Diagnosis & Management**

**Formal Treatment/Management Guidelines**

- Orphanet: National Retinoblastoma Strategy Canadian Guidelines for Care
Genetic Testing Information

• What is genetic testing?
  /primer/testing/genetictesting

• Genetic Testing Registry: Retinoblastoma

Research Studies from ClinicalTrials.gov

• ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22retinoblastoma%22

Other Diagnosis and Management Resources

• GeneReview: Retinoblastoma
  https://www.ncbi.nlm.nih.gov/books/NBK1452

• Genomics Education Programme (UK)
  https://www.genomicseducation.hee.nhs.uk/documents/retinoblastoma/

• MedlinePlus Encyclopedia: Retinoblastoma
  https://medlineplus.gov/ency/article/001030.htm

• National Cancer Institute: Genetic Testing for Hereditary Cancer Syndromes

Additional Information & Resources

Health Information from MedlinePlus

• Encyclopedia: Retinoblastoma
  https://medlineplus.gov/ency/article/001030.htm

• Health Topic: Eye Cancer
  https://medlineplus.gov/eyecancer.html

• Health Topic: Retinal Disorders
  https://medlineplus.gov/retinaldisorders.html

Genetic and Rare Diseases Information Center

• Retinoblastoma
  https://rarediseases.info.nih.gov/diseases/7563/retinoblastoma

Additional NIH Resources

• National Cancer Institute
  https://www.cancer.gov/types/retinoblastoma

• National Eye Institute
Educational Resources

- Boston Children's Hospital
  http://www.childrenshospital.org/conditions-and-treatments/conditions/r/retinoblastoma

- Digital Journal of Ophthalmology
  http://www.djo.harvard.edu/site.php?url=/patients/pi/436#

- KidsHealth from the Nemours Foundation

- MalaCards: retinoblastoma
  https://www.malacards.org/card/retinoblastoma

- Merck Manual Consumer Version

- Orphanet: Retinoblastoma
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=790

Patient Support and Advocacy Resources

- American Cancer Society
  https://www.cancer.org/cancer/retinoblastoma.html

- American Childhood Cancer Organization
  https://www.acco.org/

- Childhood Eye Cancer Trust (UK)
  https://chect.org.uk/

- CureSearch (the Children's Oncology Group and the National Childhood Cancer Foundation)
  https://curesearch.org/Retinoblastoma-in-Children

- National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/retinoblastoma/

- Resource list from the University of Kansas Medical Center
  http://www.kumc.edu/gec/support/retinobl.html

- The EyeCare Foundation
  http://www.eyecancercure.com/

- World Eye Cancer Hope
  https://wechope.org/

Clinical Information from GeneReviews

- Retinoblastoma
  https://www.ncbi.nlm.nih.gov/books/NBK1452
**Scientific Articles on PubMed**

- **PubMed**
  
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Retinoblastoma%5BMAJR%5D%29+AND+%28retinoblastoma%5BTI%5D%29+AND+review%5Bpt%5D+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D

- **Catalog of Genes and Diseases from OMIM**
  
  RETINOBLASTOMA
  
  http://omim.org/entry/180200

**Sources for This Summary**

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10450867

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17437278

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16936755

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28211617
  
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345671/

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301625

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18446017

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27488068

  
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19125074

---

*page 5*
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23498719

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18854698

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9497263
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1376960/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27712844

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28399338


Reviewed: December 2017
Published: November 26, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services